SR Fernades et al. Inflammatory Bowel Diseases, izad272, https://doi.org/10.1093/ibd/izad272 Proactive Infliximab Monitoring Improves the Rates of Transmural Remission in Crohn’s Disease: A Propensity Score–Matched Analysis
Methods: Retrospective cohort study (n=195) including consecutive CD patients starting treatment with IFX. Rates of transmural remission were compared between patients with and without therapeutic drug monitoring (target level: 5-7 µg/mL).
Key findings:
- The rates of transmural remission were higher in patients under proactive therapeutic drug monitoring (37.2% vs 18.3%; P = .004) with similar results in the propensity score–matched analysis (34.2% vs 17.1%; P = .025).
- In multivariate analysis, proactive therapeutic drug monitoring was independently associated with transmural remission (odds ratio, 2.95)
My take: Proactive therapeutic monitoring is beneficial in improving outcomes in patients with Crohn’s disease. Higher drug levels are likely to be particularly important to achieve adequate tissue penetration in transmural Crohn’s disease.
Related blog posts:
- Expert Consensus: New Recommendations for Therapeutic Drug Monitoring (2021)
- Kids Are Different: Therapeutic Drug Monitoring‘
- Proactive Therapeutic Drug Monitoring in Pediatric Crohn’s disease -Better Outcomes
- Real-World Experience with Proactive Therapeutic Drug Monitoring in Inflammatory Bowel Disease
- For the Next Insurance Appeal: Therapeutic Drug Monitoring in Adalimumab Treatment (Pediatrics) & Satire on Prior Authorizations
- Combination Therapy Study Points to Central Role of Adequate Drug Levels | gutsandgrowth
- Proactive Therapeutic Drug Monitoring -Different Time Points | gutsandgrowth
gutsandgrowth 